380 related articles for article (PubMed ID: 35431172)
1. Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction.
Nicholls SJ; Kataoka Y; Nissen SE; Prati F; Windecker S; Puri R; Hucko T; Aradi D; Herrman JR; Hermanides RS; Wang B; Wang H; Butters J; Di Giovanni G; Jones S; Pompili G; Psaltis PJ
JACC Cardiovasc Imaging; 2022 Jul; 15(7):1308-1321. PubMed ID: 35431172
[TBL] [Abstract][Full Text] [Related]
2. Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial.
Räber L; Ueki Y; Otsuka T; Losdat S; Häner JD; Lonborg J; Fahrni G; Iglesias JF; van Geuns RJ; Ondracek AS; Radu Juul Jensen MD; Zanchin C; Stortecky S; Spirk D; Siontis GCM; Saleh L; Matter CM; Daemen J; Mach F; Heg D; Windecker S; Engstrøm T; Lang IM; Koskinas KC;
JAMA; 2022 May; 327(18):1771-1781. PubMed ID: 35368058
[TBL] [Abstract][Full Text] [Related]
3. Effect of Evolocumab on Coronary Plaque Composition.
Nicholls SJ; Puri R; Anderson T; Ballantyne CM; Cho L; Kastelein JJP; Koenig W; Somaratne R; Kassahun H; Yang J; Wasserman SM; Honda S; Shishikura D; Scherer DJ; Borgman M; Brennan DM; Wolski K; Nissen SE
J Am Coll Cardiol; 2018 Oct; 72(17):2012-2021. PubMed ID: 30336824
[TBL] [Abstract][Full Text] [Related]
4. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
Nicholls SJ; Puri R; Anderson T; Ballantyne CM; Cho L; Kastelein JJ; Koenig W; Somaratne R; Kassahun H; Yang J; Wasserman SM; Scott R; Ungi I; Podolec J; Ophuis AO; Cornel JH; Borgman M; Brennan DM; Nissen SE
JAMA; 2016 Dec; 316(22):2373-2384. PubMed ID: 27846344
[TBL] [Abstract][Full Text] [Related]
5. Effect of evolocumab therapy on coronary fibrous cap thickness assessed by optical coherence tomography in patients with acute coronary syndrome.
Yano H; Horinaka S; Ishimitsu T
J Cardiol; 2020 Mar; 75(3):289-295. PubMed ID: 31495548
[TBL] [Abstract][Full Text] [Related]
6. Effects of the PCSK9 antibody alirocumab on coronary atherosclerosis in patients with acute myocardial infarction: a serial, multivessel, intravascular ultrasound, near-infrared spectroscopy and optical coherence tomography imaging study-Rationale and design of the PACMAN-AMI trial.
Zanchin C; Koskinas KC; Ueki Y; Losdat S; Häner JD; Bär S; Otsuka T; Inderkum A; Jensen MRJ; Lonborg J; Fahrni G; Ondracek AS; Daemen J; van Geuns RJ; Iglesias JF; Matter CM; Spirk D; Juni P; Mach F; Heg D; Engstrom T; Lang I; Windecker S; Räber L
Am Heart J; 2021 Aug; 238():33-44. PubMed ID: 33951415
[TBL] [Abstract][Full Text] [Related]
7. Effect of combining evolocumab with statin on carotid intraplaque neovascularization in patients with premature coronary artery disease (EPOCH).
Han Y; Ren L; Fei X; Wang J; Chen T; Guo J; Wang Q
Atherosclerosis; 2024 Apr; 391():117471. PubMed ID: 38493669
[TBL] [Abstract][Full Text] [Related]
8. Changes in Coronary Plaque Composition in Patients With Acute Myocardial Infarction Treated With High-Intensity Statin Therapy (IBIS-4): A Serial Optical Coherence Tomography Study.
Räber L; Koskinas KC; Yamaji K; Taniwaki M; Roffi M; Holmvang L; Garcia Garcia HM; Zanchin T; Maldonado R; Moschovitis A; Pedrazzini G; Zaugg S; Dijkstra J; Matter CM; Serruys PW; Lüscher TF; Kelbaek H; Karagiannis A; Radu MD; Windecker S
JACC Cardiovasc Imaging; 2019 Aug; 12(8 Pt 1):1518-1528. PubMed ID: 30553686
[TBL] [Abstract][Full Text] [Related]
9. Additive effects of ezetimibe, evolocumab, and alirocumab on plaque burden and lipid content as assessed by intravascular ultrasound: A PRISMA-compliant meta-analysis.
Liang D; Li C; Tu Y; Li Z; Zhang M
Medicine (Baltimore); 2022 Oct; 101(41):e31199. PubMed ID: 36254013
[TBL] [Abstract][Full Text] [Related]
10. Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV).
Puri R; Nissen SE; Somaratne R; Cho L; Kastelein JJ; Ballantyne CM; Koenig W; Anderson TJ; Yang J; Kassahun H; Wasserman SM; Scott R; Borgman M; Nicholls SJ
Am Heart J; 2016 Jun; 176():83-92. PubMed ID: 27264224
[TBL] [Abstract][Full Text] [Related]
11. Effect of alirocumab on coronary plaque in patients with coronary artery disease assessed by optical coherence tomography.
Gao F; Wang ZJ; Ma XT; Shen H; Yang LX; Zhou YJ
Lipids Health Dis; 2021 Sep; 20(1):106. PubMed ID: 34511134
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease.
O'Donoghue ML; Giugliano RP; Wiviott SD; Atar D; Keech A; Kuder JF; Im K; Murphy SA; Flores-Arredondo JH; López JAG; Elliott-Davey M; Wang B; Monsalvo ML; Abbasi S; Sabatine MS
Circulation; 2022 Oct; 146(15):1109-1119. PubMed ID: 36031810
[TBL] [Abstract][Full Text] [Related]
13. Effects of alirocumab on endothelial function and coronary atherosclerosis in myocardial infarction: A PACMAN-AMI randomized clinical trial substudy.
Rexhaj E; Bär S; Soria R; Ueki Y; Häner JD; Otsuka T; Kavaliauskaite R; Siontis GC; Stortecky S; Shibutani H; Spirk D; Engstrøm T; Lang I; Morf L; Ambühl M; Windecker S; Losdat S; Koskinas KC; Räber L;
Atherosclerosis; 2024 May; 392():117504. PubMed ID: 38513436
[TBL] [Abstract][Full Text] [Related]
14. Concomitant Coronary Atheroma Regression and Stabilization in Response to Lipid-Lowering Therapy.
Biccirè FG; Häner J; Losdat S; Ueki Y; Shibutani H; Otsuka T; Kakizaki R; Hofbauer TM; van Geuns RJ; Stortecky S; Siontis GCM; Bär S; Lønborg J; Heg D; Kaiser C; Spirk D; Daemen J; Iglesias JF; Windecker S; Engstrøm T; Lang I; Koskinas KC; Räber L
J Am Coll Cardiol; 2023 Oct; 82(18):1737-1747. PubMed ID: 37640248
[TBL] [Abstract][Full Text] [Related]
15. Impact of PCSK9 inhibitors on coronary atheroma phenotype following myocardial infarction: insights from intravascular imaging.
Abrahams T; Fujino M; Nelson AJ; Nicholls SJ
Curr Opin Cardiol; 2023 Nov; 38(6):504-508. PubMed ID: 37751373
[TBL] [Abstract][Full Text] [Related]
16. Changes of coronary plaque composition correlate with C-reactive protein levels in patients with ST-elevation myocardial infarction following high-intensity statin therapy.
Koskinas KC; Zaugg S; Yamaji K; García-García HM; Taniwaki M; Klingenberg R; Moschovitis A; Lüscher TF; van Tits LJ; Matter CM; Windecker S; Räber L
Atherosclerosis; 2016 Apr; 247():154-60. PubMed ID: 26921743
[TBL] [Abstract][Full Text] [Related]
17. Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab: An Analysis of FOURIER Trial Data.
Qamar A; Giugliano RP; Keech AC; Kuder JF; Murphy SA; Kurtz CE; Wasserman SM; Sever PS; Pedersen TR; Sabatine MS
JAMA Cardiol; 2019 Jan; 4(1):59-63. PubMed ID: 30540337
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of alirocumab for reducing plaque vulnerability: Study protocol for ALTAIR, a randomized controlled trial in Japanese patients with coronary artery disease receiving rosuvastatin.
Otake H; Sugizaki Y; Toba T; Nagano Y; Tsukiyama Y; Yanaka KI; Yamamoto H; Nagasawa A; Onishi H; Takeshige R; Nakano S; Matsuoka Y; Tanimura K; Kawamori H; Shinke T; Hirata KI
J Cardiol; 2019 Mar; 73(3):228-232. PubMed ID: 30579806
[TBL] [Abstract][Full Text] [Related]
19. Assessing the impact of PCSK9 inhibition on coronary plaque phenotype with optical coherence tomography: rationale and design of the randomized, placebo-controlled HUYGENS study.
Nicholls SJ; Nissen SE; Prati F; Windecker S; Kataoka Y; Puri R; Hucko T; Kassahun H; Liao J; Somaratne R; Butters J; Di Giovanni G; Jones S; Psaltis PJ
Cardiovasc Diagn Ther; 2021 Feb; 11(1):120-129. PubMed ID: 33708484
[TBL] [Abstract][Full Text] [Related]
20. Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction.
Schwartz GG; Giugliano RP
Curr Opin Lipidol; 2022 Jun; 33(3):147-159. PubMed ID: 35695614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
